Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q2 2021 call → NOWe need to determine if management explains where the company's business is going by narrating what its counterparties are themselves doing and scaling. The counterparties here could be partners like DyDo Pharma, KYE Pharmaceuticals, or perhaps the physicians and patients? But the question is about specific counterparties that the company already supplies or serves, and whose growth drives the company's coming volume. Let's analyze the transcript. Management discusses their own sales, marketing efforts, R&D, business development. They mention partnerships with DyDo Pharma (Japan) and KYE (Canada). For DyDo, they received $2.7 million in revenue from the license agreement. But do they describe DyDo's own trajectory? They say "we are gratified to continue the expansion of our global footprint for Firdapse" but no detail on DyDo's plans. For KYE, they say "KYE continues to make progress within the LEMS community in Canada." That's vague. No substantial narration of counterparties' own ramps. They also discuss physicians' practices being impacted by COVID, but that's not a counterparty they supply. They talk about patient enrollments, but those are end customers, not counterparties with their own trajectories. The question specifically asks: "does a substantial part of management's forward account consist of reporting on the growth, expansion, ramp, adoption, or program build-out of specific customers, partners, licensees, distributors, payers, operators, or programs the company ALREADY SUPPLIES OR SERVES?" Here, the only partners are DyDo and KYE, but management does not describe their own expansion plans in detail. They just mention they are making progress. No specifics on their launches, capacity, etc. Management's forward account is mostly about their own efforts: commercial field force, patient resources, R&D, business development, and potential acquisitions. They talk about market dynamics and COVID impact. They do not narrate counterparties' trajectories as the driver. Thus, answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.